<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732758</url>
  </required_header>
  <id_info>
    <org_study_id>1K23HD052550-01A2</org_study_id>
    <secondary_id>1K23HD052550-01A2</secondary_id>
    <nct_id>NCT00732758</nct_id>
  </id_info>
  <brief_title>Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3</brief_title>
  <acronym>Vitamin D RCT</acronym>
  <official_title>Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to characterize the threshold levels of serum 25-hydroxyvitamin D for
      the definition of vitamin D insufficiency in 8-14 year old African American and Caucasian
      children.

      We propose a 6 month randomized placebo controlled trial of vitamin D (vitamin D3 1000 IU/day
      vs. placebo) initiated during October through March (during fall and winter) in 8 to 14 year
      old African American and Caucasian children. The results of the trial will help establish the
      cutoff threshold value of serum 25(OH)D for defining vitamin D insufficiency in preadolescent
      and adolescent children. Safety of vitamin D supplementation will be assessed by measuring
      serum calcium at 0, 2 and 6 months and by monitoring for adverse events. Currently
      recommended adequate intake for vitamin D of 200 IU daily may not meet the body's daily needs
      for vitamin D. Therefore, it is likely that a higher level of daily vitamin D intake may be
      needed to meet the body's skeletal and non-skeletal demands for vitamin D. Determining the
      dietary required intake of vitamin D for the prevention of vitamin D insufficiency during
      childhood has immense public health potential for addressing health disparities and ensuring
      better bone health during adulthood. The primary outcome measure will be serum 25(OH)D and
      parathyroid hormone (PTH). The secondary outcome measures will include: markers of bone
      formation (serum P1NP) and bone resorption (serum CTX).We will also examine differences in
      serum 25(OH)D, PTH, and markers of bone turnover in African American vs. Caucasian children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiologic and clinical data document a high prevalence of vitamin D insufficiency among
      adults and adolescents in the US. Vitamin D insufficiency during childhood has the potential
      to impact the acquisition of peak bone mass. Vitamin D insufficiency is also associated with
      several non-skeletal disorders including cancer (prostate, breast, and colon), diabetes
      mellitus (type 1 and type 2), and multiple sclerosis. In our pilot study nearly 50% of 6 to
      10 year old African American children residing in Pittsburgh, Pennsylvania, were deemed
      vitamin D insufficient (serum 25-hydroxyvitamin D (25(OH)D): â‰¤ 20 ng/mL; Rajakumar K, et al.
      Clinical Pediatrics. 2005;44:683-692). To extend this field further, we are proposing a
      randomized placebo-controlled trial of vitamin D3 for establishing the serum
      25-hydroxyvitamin D (25(OH)D) cutoff threshold levels for defining vitamin D insufficiency
      during childhood and to document the safety and efficacy of treatment on the vitamin D status
      of the study cohort. A total of 168 (African American: 84, Caucasian: 84) 8 to 14 year old
      preadolescent and adolescent children will undergo a randomized-placebo controlled trial
      (RCT) of vitamin D3 1000 IU daily vs. placebo for 6 months initiated during fall and winter
      (October through March). Safety of vitamin D supplementation will be assessed by measuring
      serum calcium at 0, 2 and 6 months and by monitoring for adverse events. We will also examine
      the differences in serum 25(OH)D, PTH, and markers of bone turnover in African American vs.
      Caucasian children. The primary outcome measure will be serum 25(OH)D and PTH. The secondary
      outcome measures will include: markers of bone formation: serum osteocalcin (OC) and bone
      resorption: serum C-terminal cross-linking telopeptide of type 1 collagen (serum CTX).
      Additional outcomes will include: dietary intake of vitamin D and calcium, skin color
      (Fitzpatrick Sunreactive Skin Type and Melanin Index), sun exposure, and body mass index.
      Vitamin D deficiency will be defined as serum 25-hydroxyvitamin D concentrations &lt;20 ng/mL.
      Public health importance of childhood vitamin D insufficiency is linked to the impact of
      vitamin D status on the acquisition of peak bone mass. Reduced peak bone mass can predispose
      to premature onset of osteoporosis and increase the risk for osteoporosis related fragility
      fractures. Achieving and maintaining vitamin D sufficiency during childhood can positively
      impact the skeletal health of children and reduce their &quot;osteoporosis&quot; burden during
      adulthood, and modify their risk for the non-skeletal disorders associated with chronic
      vitamin D insufficiency. Paucity of data regarding threshold levels of serum 25(OH)D
      associated with vitamin D insufficiency status among school age children and the likelihood
      that the serum 25(OH)D threshold levels for vitamin D sufficiency could be different among
      African American and Caucasian children makes it compelling for this issue to be explored.
      Based on expert opinion and supportive data in the medical literature, we feel that the
      currently recommended adequate intake for vitamin D for pre- and adolescent children (200 IU
      daily) is woefully inadequate to meet the daily needs for vitamin D. Therefore, it is likely
      that a higher level of daily vitamin D intake may be needed to meet the body's skeletal and
      non-skeletal demands for vitamin D. This study will determine the serum 25(OH)D cutoff for
      the definition of vitamin D insufficiency and document the safety and efficacy of treatment
      on vitamin D status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25-hydroxyvitamin D</measure>
    <time_frame>6 months</time_frame>
    <description>Circulating concentration of 25 hydroxyvitamin D is a biomarker of vitamin D status. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D concentrations &lt;20 ng/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parathyroid Hormone (PTH) Dietary Data</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin (OC)</measure>
    <time_frame>6 months</time_frame>
    <description>Marker of bone formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collagen Type 1 Cross-linked C-telopeptide (CTx)</measure>
    <time_frame>6 months</time_frame>
    <description>Collagen type 1 cross-linked C-telopeptide (CTx) is a marker of bone resorption.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 1000 IU Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 1000 IU</intervention_name>
    <description>Vitamin D3 1000 IU Tablet once daily for 6 months</description>
    <arm_group_label>Vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Placebo Tablet once daily for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 8-14 years

          -  Race: African American or Caucasian

          -  Children not taking multivitamins for at least 1 month before enrollment and agree not
             to start any multivitamin supplements during the 6-month trial period.

          -  Children who are on multivitamins can be considered for enrollment only if they are
             able to and agree to stop their multivitamin tablet for a 1 month washout period prior
             to enrollment.

          -  Absence of chronic diseases that could affect growth or calcium or vitamin D
             metabolism

        Exclusion Criteria:

          -  Hepatic or renal disease

          -  Metabolic rickets

          -  Malabsorptive disorders (Crohn's disease, cystic fibrosis and celiac disease) or
             cancer

          -  Treatment with anticonvulsants or systemic glucocorticoids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kumaravel Rajakumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rajakumar K, Moore CG, Yabes J, Olabopo F, Haralam MA, Comer D, Bogusz J, Nucci A, Sereika S, Dunbar-Jacob J, Holick MF, Greenspan SL. Effect of Vitamin D3 Supplementation in Black and in White Children: A Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2015 Aug;100(8):3183-92. doi: 10.1210/jc.2015-1643. Epub 2015 Jun 19.</citation>
    <PMID>26091202</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <results_first_submitted>September 22, 2015</results_first_submitted>
  <results_first_submitted_qc>September 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2015</results_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Kumaravel Rajakumar</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Vitamin D Insufficiency</keyword>
  <keyword>Child</keyword>
  <keyword>Adolescent</keyword>
  <keyword>African American</keyword>
  <keyword>Caucasian</keyword>
  <keyword>Definition</keyword>
  <keyword>Preadolescent</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We enrolled healthy 8- to 14-year-old children from October through March of 2008 through 2011.</recruitment_details>
      <pre_assignment_details>Children receiving vitamin preparations underwent a 1-month washout before enrollment. Of 355 children assessed for eligibility, 304 were deemed eligible and among these 157 agreed to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3 Group</title>
          <description>Vitamin D3 1000 IU Tablet
Vitamin D3 1000 IU: Vitamin D3 1000 IU Tablet once daily for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Placebo Tablet
Placebo Tablet: Placebo Tablet once daily for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3 Group</title>
          <description>Vitamin D3 1000 IU Tablet
Vitamin D3 1000 IU: Vitamin D3 1000 IU Tablet once daily for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo Tablet
Placebo Tablet: Placebo Tablet once daily for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="1.9"/>
                    <measurement group_id="B2" value="11.4" spread="2.0"/>
                    <measurement group_id="B3" value="11.3" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilograms/meters^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.6" spread="5.5"/>
                    <measurement group_id="B2" value="21.6" spread="6.2"/>
                    <measurement group_id="B3" value="21.6" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Skin Type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I (easy burn, no tan)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II (easy burn, slight tan)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III (burn, then tan)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV (no burn, good tan)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V (never burn, marked tan)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin D-deficient: Defined as serum 25(OH)D &lt;20 ng/mL</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>25(OH)D&lt;20 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25(OH)D&gt;20 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum 25-hydroxyvitamin D</title>
        <description>Circulating concentration of 25 hydroxyvitamin D is a biomarker of vitamin D status. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D concentrations &lt;20 ng/mL.</description>
        <time_frame>6 months</time_frame>
        <population>Intention to treat -- participants analyzed based on the group to which they were randomized but only included in the analysis if they had follow up data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 Group</title>
            <description>Vitamin D3 1000 IU Tablet
Vitamin D3 1000 IU: Vitamin D3 1000 IU Tablet once daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo Tablet
Placebo Tablet: Placebo Tablet once daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum 25-hydroxyvitamin D</title>
          <description>Circulating concentration of 25 hydroxyvitamin D is a biomarker of vitamin D status. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D concentrations &lt;20 ng/mL.</description>
          <population>Intention to treat -- participants analyzed based on the group to which they were randomized but only included in the analysis if they had follow up data at 6 months.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" spread="7.6"/>
                    <measurement group_id="O2" value="22.4" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>adjusting for baseline 25(OH)D, race, BMI, diet vitamin D, gender, pubertal status, and sunlight exposure.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parathyroid Hormone (PTH) Dietary Data</title>
        <time_frame>6 months</time_frame>
        <population>Intention to treat with participants analyzed by the group to which they were assigned but only analyzing those participants with follow up data for PTH at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 Group</title>
            <description>Vitamin D3 1000 IU Tablet
Vitamin D3 1000 IU: Vitamin D3 1000 IU Tablet once daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo Tablet
Placebo Tablet: Placebo Tablet once daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Parathyroid Hormone (PTH) Dietary Data</title>
          <population>Intention to treat with participants analyzed by the group to which they were assigned but only analyzing those participants with follow up data for PTH at 6 months.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" spread="16.3"/>
                    <measurement group_id="O2" value="33.5" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>unadjusted p-values</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Osteocalcin (OC)</title>
        <description>Marker of bone formation</description>
        <time_frame>6 months</time_frame>
        <population>Intention to treat with participants analyzed in the group to which they were assigned but only using participants with 6 month OC data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 Group</title>
            <description>Vitamin D3 1000 IU Tablet
Vitamin D3 1000 IU: Vitamin D3 1000 IU Tablet once daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo Tablet
Placebo Tablet: Placebo Tablet once daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Osteocalcin (OC)</title>
          <description>Marker of bone formation</description>
          <population>Intention to treat with participants analyzed in the group to which they were assigned but only using participants with 6 month OC data available.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.1" spread="48.3"/>
                    <measurement group_id="O2" value="104.8" spread="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Collagen Type 1 Cross-linked C-telopeptide (CTx)</title>
        <description>Collagen type 1 cross-linked C-telopeptide (CTx) is a marker of bone resorption.</description>
        <time_frame>6 months</time_frame>
        <population>Intention to treat with participants analyzed by the group to which they were assigned but only analyzing participants with 6 month CTx data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 Group</title>
            <description>Vitamin D3 1000 IU Tablet
Vitamin D3 1000 IU: Vitamin D3 1000 IU Tablet once daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo Tablet
Placebo Tablet: Placebo Tablet once daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Collagen Type 1 Cross-linked C-telopeptide (CTx)</title>
          <description>Collagen type 1 cross-linked C-telopeptide (CTx) is a marker of bone resorption.</description>
          <population>Intention to treat with participants analyzed by the group to which they were assigned but only analyzing participants with 6 month CTx data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.9"/>
                    <measurement group_id="O2" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D3 Group</title>
          <description>Vitamin D3 1000 IU Tablet
Vitamin D3 1000 IU: Vitamin D3 1000 IU Tablet once daily for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Placebo Tablet
Placebo Tablet: Placebo Tablet once daily for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kumaravel Rajakumar</name_or_title>
      <organization>Children's Hospital of Pittsburgh</organization>
      <phone>412-692-5822</phone>
      <email>rajakumark@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

